BACKGROUND: We previously reported that the cytochrome P450 product 20-hydroxyeicosatetraenoic acid has prosurvival effects in pulmonary artery endothelial cells and ex vivo pulmonary arteries. We tested the potential of a 20-hydroxyeicosatetraenoic acid analog N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine (20-5,14-HEDGE) to protect against lung ischemic reperfusion injury in rats. Furthermore, we examined activation of innate immune system components, high mobility group box 1 (HMGB1) and toll-like receptor 4 (TLR4), in this model as well as the effect of 20-5,14-HEDGE on this signaling pathway. METHODS: Sprague-Dawley rats treated with 20-5,14-HEDGE or vehicle were subjected to surgically induced, unilateral lung ischemia for 60 minutes followed by reperfusion for 2 hours in vivo. Injury was assessed histologically by hematoxylin and eosin, and with identification of myeloperoxidase immunohistochemically. The HMGB1 and TLR4 proteins were identified by Western blot. Caspase 3 activity or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole, incorporation were used to measure apoptosis and cell survival. RESULTS: The ischemia reperfusion injury evoked atelectasis and hemorrhage, an influx of polymorphonuclear cells, and increased TLR4 and HMGB1 expression. Caspase 3 activity was increased, and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide incorporation was decreased. The 20-5,14-HEDGE protected against each of these endpoints, including infiltration of polymorphonuclear cells, with no changes in caspase 3 activity in other organs. CONCLUSIONS: Lung ischemia reperfusion produces apoptosis and activation of the innate immune system including HMGB1 and TLR4 within 2 hours of reperfusion. Treatment with 20-5,14-HEDGE decreases activation of this response system, and salvages lung tissue.
BACKGROUND: We previously reported that the cytochrome P450 product 20-hydroxyeicosatetraenoic acid has prosurvival effects in pulmonary artery endothelial cells and ex vivo pulmonary arteries. We tested the potential of a 20-hydroxyeicosatetraenoic acid analog N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine (20-5,14-HEDGE) to protect against lung ischemic reperfusion injury in rats. Furthermore, we examined activation of innate immune system components, high mobility group box 1 (HMGB1) and toll-like receptor 4 (TLR4), in this model as well as the effect of 20-5,14-HEDGE on this signaling pathway. METHODS:Sprague-Dawley rats treated with 20-5,14-HEDGE or vehicle were subjected to surgically induced, unilateral lung ischemia for 60 minutes followed by reperfusion for 2 hours in vivo. Injury was assessed histologically by hematoxylin and eosin, and with identification of myeloperoxidase immunohistochemically. The HMGB1 and TLR4 proteins were identified by Western blot. Caspase 3 activity or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole, incorporation were used to measure apoptosis and cell survival. RESULTS: The ischemia reperfusion injury evoked atelectasis and hemorrhage, an influx of polymorphonuclear cells, and increased TLR4 and HMGB1 expression. Caspase 3 activity was increased, and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide incorporation was decreased. The 20-5,14-HEDGE protected against each of these endpoints, including infiltration of polymorphonuclear cells, with no changes in caspase 3 activity in other organs. CONCLUSIONS: Lung ischemia reperfusion produces apoptosis and activation of the innate immune system including HMGB1 and TLR4 within 2 hours of reperfusion. Treatment with 20-5,14-HEDGE decreases activation of this response system, and salvages lung tissue.
Authors: Kasem Nithipatikom; Eric R Gross; Michael P Endsley; Jeannine M Moore; Marilyn A Isbell; John R Falck; William B Campbell; Garrett J Gross Journal: Circ Res Date: 2004-09-23 Impact factor: 17.367
Authors: Yuenmu Chen; Meetha Medhora; John R Falck; Kirkwood A Pritchard; Elizabeth R Jacobs Journal: Am J Physiol Lung Cell Mol Physiol Date: 2006-05-05 Impact factor: 5.464
Authors: Elizabeth R Jacobs; Sreedhar Bodiga; Irshad Ali; Aaron M Falck; John R Falck; Meetha Medhora; Anuradha Dhanasekaran Journal: Exp Cell Res Date: 2012-06-09 Impact factor: 3.905
Authors: John C Densmore; Terry R Schaid; Paul M Jeziorczak; Meetha Medhora; Said Audi; Shraddha Nayak; John Auchampach; Melinda R Dwinell; Aron M Geurts; Elizabeth R Jacobs Journal: Exp Lung Res Date: 2017-03-07 Impact factor: 2.459
Authors: Irshad Ali; Rahul Nanchal; Fouad Husnain; Said Audi; G Ganesh Konduri; John C Densmore; Meetha Medhora; Elizabeth R Jacobs Journal: Pulm Circ Date: 2013-12-04 Impact factor: 3.017
Authors: Mahsa Ranji; Mohammad Masoudi Motlagh; Fahimeh Salehpour; Reyhaneh Sepehr; James S Heisner; Ranjan K Dash; Amadou K S Camara Journal: IEEE J Transl Eng Health Med Date: 2016-06-15 Impact factor: 3.316
Authors: Said H Audi; Elizabeth R Jacobs; Ming Zhao; David L Roerig; Steven T Haworth; Anne V Clough Journal: Nucl Med Biol Date: 2014-08-19 Impact factor: 2.408
Authors: John C Densmore; Paul M Jeziorczak; Anne V Clough; Kirkwood A Pritchard; Breana Cummens; Meetha Medhora; Arjun Rao; Elizabeth R Jacobs Journal: Shock Date: 2013-03 Impact factor: 3.454